American Century Companies Inc. Acquires 24,132 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

American Century Companies Inc. raised its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 3.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 839,203 shares of the biotechnology company’s stock after purchasing an additional 24,132 shares during the period. American Century Companies Inc.’s holdings in Blueprint Medicines were worth $73,195,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in BPMC. Quarry LP purchased a new stake in shares of Blueprint Medicines in the 3rd quarter worth approximately $32,000. R Squared Ltd bought a new stake in Blueprint Medicines in the fourth quarter worth $51,000. Asset Management One Co. Ltd. purchased a new stake in shares of Blueprint Medicines in the fourth quarter worth $88,000. Van ECK Associates Corp increased its holdings in shares of Blueprint Medicines by 48.2% during the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $97,000 after acquiring an additional 363 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new position in shares of Blueprint Medicines in the 3rd quarter worth about $108,000.

Insider Activity

In other news, Director Jeffrey W. Albers sold 15,161 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $109.53, for a total transaction of $1,660,584.33. Following the sale, the director now directly owns 152,396 shares in the company, valued at $16,691,933.88. This trade represents a 9.05 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ariel Hurley sold 2,250 shares of the company’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $100.00, for a total transaction of $225,000.00. Following the completion of the transaction, the insider now directly owns 14,967 shares of the company’s stock, valued at $1,496,700. This represents a 13.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 29,334 shares of company stock valued at $3,103,512 in the last ninety days. Corporate insiders own 4.21% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Morgan Stanley initiated coverage on shares of Blueprint Medicines in a research note on Thursday, March 20th. They set an “equal weight” rating and a $100.00 price objective for the company. Scotiabank initiated coverage on shares of Blueprint Medicines in a research report on Friday, March 7th. They set a “sector outperform” rating and a $150.00 price target for the company. Piper Sandler boosted their price objective on shares of Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Wolfe Research initiated coverage on Blueprint Medicines in a research note on Tuesday, March 18th. They set an “outperform” rating on the stock. Finally, Guggenheim restated a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $124.95.

Blueprint Medicines Trading Down 2.3 %

Shares of Blueprint Medicines stock opened at $93.08 on Wednesday. Blueprint Medicines Co. has a 1-year low of $80.68 and a 1-year high of $121.90. The company’s fifty day simple moving average is $99.12 and its 200-day simple moving average is $93.97. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The stock has a market capitalization of $5.95 billion, a PE ratio of -86.18 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. As a group, equities analysts anticipate that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.